20020902
 Merck's Cozaar Fails To Exceed Generic In Heart-Drug Trial   The Wall Street Journal,  Sep 3, 2002  Cozaar is one of a handful of drugs Merck views as crucial for future growth. The medicine has been locked in a fierce battle with Diovan, a similar drug marketed by Novartis AG. Another hot-selling drug in the category is Avapro, co-marketed by Sanofi-Synthelabo and Bristol-Myers Squibb Co.   
